Characteristics and Treatment of Hairy Cell Leukaemia

[1] Oleske, D. et al. A case-control inquiry into the etiology of hairy cell leukemia. Am J Epidemiol 1985; 121(5): 675-683.10.1093/aje/121.5.675Search in Google Scholar

[2] Arons, E. et al. VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy. Blood 2009; 114(21): 4687-4695.10.1182/blood-2009-01-201731Search in Google Scholar

[3] Matutes, E. et al. The immunophenotype of hairy cell leukemia (HCL). Proposal for a scoring system to distinguish HCL from B-cell disorders with hairy or villous lymphocytes. Leukemia Lymph, 1994; 14(1): 57-61.Search in Google Scholar

[4] Falini, B. et al.: Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet 2004; 363(9424): 869-1871.10.1016/S0140-6736(04)16356-3Search in Google Scholar

[5] Tiacci, E. et al.: BRAF mutations in hairy-cell leukemia. N Engl J Med 2011; 364(24): 2305-2315.10.1056/NEJMoa1014209368958521663470Search in Google Scholar

[6] Steis, R.G. et al. Serum solubile IL-2 receptor as a tumor marker in patients with hairy cell leukemia. Blood 1988; 71(5): 1304-1309.10.1182/blood.V71.5.1304.1304Search in Google Scholar

[7] Polliack, A. Hairy cell leukemia: biology, clinical diagnosis, unusual manifestations and associated disorders. Rev Clin Exp Hematol 2002; 6(4): 366-388.10.1046/j.1468-0734.2002.00304.x12823778Search in Google Scholar

[8] Hisada, M., et al. Second cancer incidence and cause-specifc mortality among 3104 patients with hairy cell leukaemia: a population-based study. J Natl Cancer Inst 2007; 99(3): 215-222.10.1093/jnci/djk03017284716Search in Google Scholar

[9] Seshadri, P. and Seshadri, R. Hairy cell leukemia: treatment prospects. Expert Rev Anticancer Ther 2001; 1(1): 91-98.10.1586/14737140.1.1.9112113139Search in Google Scholar

[10] Golde, D.W. Therapy of hairy-cell leukemia. N Engl J Med 1982; 307(8): 495-496.10.1056/NEJM1982081930708097099209Search in Google Scholar

[11] Frassoldati, A. et al.: Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (IC-GHCL). Leukemia Lymph, 1994; 13(3-4): 307-316.10.3109/104281994090562957519510Search in Google Scholar

[12] Robak, T. et al. 2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol 1999; 62(1): 49-56.10.1111/j.1600-0609.1999.tb01114.x9918312Search in Google Scholar

[13] Greksák, R. et al. Treatment and prognosis of the patients with hairy cell leukemia, treated in the years 1996 – 2010 at the National Cancer Institute in Bratislava Onkológia 2011; 6(4): 241-245 in slovak.Search in Google Scholar

[14] Grever, M.R.: How I treat hairy cell leukemia. Blood 2010; 115(1): 21-28.10.1182/blood-2009-06-195370280368919843881Search in Google Scholar

[15] Greksák, R.: Establishment of the diagnosis and minimal residual disease in hairy cell leukaemia by fow cytom-etry of bone marrow aspirate and imunohistochemical examination of trepanobiopsy. In Onkológia, 2012; 7(6): 406-409 in slovak.Search in Google Scholar

[16] Greksák, R. Hairy cell leukaemia – diagnostics, treatment and monoclonal antibodies, In Transfuze Hematol dnes, 2010; 16(3): 158-165 in slovak.Search in Google Scholar